Difference between revisions of "Interferon alfa-2a (Roferon-A)"
m (→References) |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Chronic myelogenous leukemia]] | *[[Chronic myelogenous leukemia]] | ||
| − | |||
*[[Hairy cell leukemia]] | *[[Hairy cell leukemia]] | ||
*[[Kaposi sarcoma]] | *[[Kaposi sarcoma]] | ||
| − | |||
*[[Neuroendocrine tumor]] | *[[Neuroendocrine tumor]] | ||
*[[Renal cell carcinoma]] | *[[Renal cell carcinoma]] | ||
| Line 17: | Line 15: | ||
==Diseases for which it was used== | ==Diseases for which it was used== | ||
| − | *[[Multiple myeloma]] | + | *[[Follicular lymphoma - historical|Follicular lymphoma]] |
| + | *[[Melanoma - historical|Melanoma]] | ||
| + | *[[Multiple myeloma - historical|Multiple myeloma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 38: | Line 38: | ||
[[Category:Chronic myelogenous leukemia medications]] | [[Category:Chronic myelogenous leukemia medications]] | ||
| − | |||
[[Category:Hairy cell leukemia medications]] | [[Category:Hairy cell leukemia medications]] | ||
[[Category:Kaposi sarcoma medications]] | [[Category:Kaposi sarcoma medications]] | ||
| − | |||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
[[Category:Renal_cell_carcinoma medications]] | [[Category:Renal_cell_carcinoma medications]] | ||
[[Category:Cutaneous squamous cell carcinoma medications]] | [[Category:Cutaneous squamous cell carcinoma medications]] | ||
| + | |||
| + | [[Category:Follicular lymphoma medications (historic)]] | ||
| + | [[Category:Melanoma medications (historic)]] | ||
| + | [[Category:Multiple myeloma medications (historic)]] | ||
[[Category:FDA approved in 1986]] | [[Category:FDA approved in 1986]] | ||
Revision as of 01:52, 28 April 2022
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic myelogenous leukemia
- Hairy cell leukemia
- Kaposi sarcoma
- Neuroendocrine tumor
- Renal cell carcinoma
- Cutaneous squamous cell carcinoma
Diseases for which it was used
Patient drug information
- Interferon alfa-2a (Roferon-A) package insert[1]
- Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)[3]
History of changes in FDA indication
- 6/4/1986: Initial FDA approval for treatment of patients 18 years of age or older with hairy cell leukemia
- Uncertain date: In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis).
Also known as
- Brand name: Laroferon, Roferon-A
References
- Drugs
- Subcutaneous medications
- Interferon alfa
- Chronic myelogenous leukemia medications
- Hairy cell leukemia medications
- Kaposi sarcoma medications
- Neuroendocrine tumor medications
- Renal cell carcinoma medications
- Cutaneous squamous cell carcinoma medications
- Follicular lymphoma medications (historic)
- Melanoma medications (historic)
- Multiple myeloma medications (historic)
- FDA approved in 1986